Literature DB >> 9797253

Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

M Tanaka1, Y Onodera, Y Uchida, K Sato.   

Abstract

Two altered GrlB proteins (one with an Asp-432-->Asn alteration and one with an Asn-470-->Asp alteration) of Staphylococcus aureus were purified as fusion proteins to maltose-binding protein. The 50% inhibitory concentrations of levofloxacin were 14 and 3.4 microg/ml against topoisomerase IV containing GrlB proteins with alterations at positions 432 and 470, respectively. These results suggest that the alteration of Asp to Asn at position 432 may be responsible for quinolone resistance.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9797253      PMCID： PMC105993     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.

Authors:  J J Goswitz; K E Willard; C E Fasching; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Crystal structure of an N-terminal fragment of the DNA gyrase B protein.

Authors:  D B Wigley; G J Davies; E J Dodson; A Maxwell; G Dodson
Journal:  Nature       Date:  1991-06-20       Impact factor: 49.962

3.  gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee.

Authors:  C E Fasching; F C Tenover; T G Slama; L M Fisher; S Sreedharan; M Oram; K Willard; L M Sinn; D N Gerding; L R Peterson
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

4.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

Authors:  S Sreedharan; M Oram; B Jensen; L R Peterson; L M Fisher
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

6.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

8.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

9.  Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.

Authors:  M Tanaka; K Sato; Y Kimura; I Hayakawa; Y Osada; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Mechanism of action of quinolones against Escherichia coli DNA gyrase.

Authors:  H Yoshida; M Nakamura; M Bogaki; H Ito; T Kojima; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191
View more
  8 in total

1.  In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  H J Linde; M Schmidt; E Fuchs; U Reischl; H H Niller; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.

Authors:  A Y Saiki; L L Shen; C M Chen; J Baranowski; C G Lerner
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase.

Authors:  Y Onodera; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 5.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.

Authors:  T Akasaka; M Tanaka; A Yamaguchi; K Sato
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Phenotypic and genotypic evaluation of fluoroquinolone resistance in clinical isolates of Staphylococcus aureus in Tehran.

Authors:  Marzieh Aligholi; Akbar Mirsalehian; Shahnaz Halimi; Hossein Imaneini; Morovat Taherikalani; Fereshteh Jabalameli; Parisa Asadollahi; Babak Mohajer; Alireza Abdollahi; Mohammad Emaneini
Journal:  Med Sci Monit       Date:  2011-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.